Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005066 · ClinicalTrials.gov registry record · Phase 2
O6-benzylguanine and Carmustine in Treating Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue Sarcoma
A Phase 2 study of Sarcoma, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 10
- Study locations
NCT00005066 is a Phase 2 study of Sarcoma that has completed, run by University of Chicago. The registered enrollment target is 12 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (99% lower). The trial reports 10 study locations across 2 states.
The verdict
NCT00005066, a Phase 2 study of Sarcoma, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 10
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining O6-benzylguanine and carmustine in treating patients who have recurrent, metastatic, or locally advanced soft tissue sarcoma.
Conditions Studied
Interventions
- DRUG O6-benzylguanine
- DRUG carmustine
Study Locations (10)
Illinois
- University of Illinois at Chicago - Chicago
- University of Chicago Cancer Research Center - Chicago
- Louis A. Weiss Memorial Hospital - Chicago
- Cancer Care Specialists of Central Illinois, S.C. - Decatur
- Evanston Northwestern Health Care - Evanston
- Division of Hematology/Oncology - Park Ridge
- Oncology/Hematology Associates of Central Illinois, P.C. - Peoria
- Central Illinois Hematology Oncology Center - Springfield
Indiana
- Fort Wayne Medical Oncology and Hematology, Inc. - Fort Wayne
- Michiana Hematology/Oncology P.C. - South Bend
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2000-06 |
| Est. Completion | 2002-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005066
The ClinicalTrials.gov registry entry for NCT00005066 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (99% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which O6-benzylguanine is the first listed.
NCT00005066 reports 10 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Indiana.
Frequently Asked Questions
What is clinical trial NCT00005066 about?
NCT00005066 is a clinical study titled "O6-benzylguanine and Carmustine in Treating Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue Sarcoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining O6-benzylguanine and carmustine in treating patients who ha...
What is the current status of trial NCT00005066?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2000-06. Estimated completion is 2002-10.
What conditions does trial NCT00005066 study?
This clinical trial studies the following conditions: Sarcoma.
What interventions are being tested in trial NCT00005066?
The interventions under investigation include: O6-benzylguanine (DRUG), carmustine (DRUG).
Who is sponsoring clinical trial NCT00005066?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005066 being conducted?
This trial has 10 study locations across Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
RECRUITING · Phase 2
-
Fluorescent Intra-operative Tumor Margin Examination
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.